Download PDF
Horm Metab Res 2011; 43(08): 562-568
DOI: 10.1055/s-0031-1280829
Humans, Clinical
Georg Thieme Verlag KG Stuttgart · NewYork

High Prevalence of TSHR/Gsα Mutation-negative Clonal Hot Thyroid Nodules (HNs) in a Turkish Cohort

S. Sancak
1   Section of Endocrinology and Metabolism of Marmara Medical School, Istanbul, Turkey
,
H. Jaeschke
2   University of Leipzig, Department for Internal Medicine, Endocrinology and Nephrology, Leipzig, Germany
,
F. Eren
3   Department of Pathology of Marmara Medical School, Istanbul, Turkey
,
O. Tarcin
1   Section of Endocrinology and Metabolism of Marmara Medical School, Istanbul, Turkey
,
B. Guellueoglu
4   Marmara Medical School, General Surgery Department, Istanbul, Turkey
,
L.S. Sen
4   Marmara Medical School, General Surgery Department, Istanbul, Turkey
,
Z. Sever
3   Department of Pathology of Marmara Medical School, Istanbul, Turkey
,
H.I. Gozu
5   Haydarpaşa Numune Education and Research Hospital, Section of Endocrinology and Metabolism, Istanbul, Turkey
,
R. Bircan
6   Namık Kemal University, Departments of Molecular Biology and Genetic, Istanbul, Turkey
,
S. Akalin
1   Section of Endocrinology and Metabolism of Marmara Medical School, Istanbul, Turkey
,
R. Paschke
2   University of Leipzig, Department for Internal Medicine, Endocrinology and Nephrology, Leipzig, Germany
,
M. Eszlinger
2   University of Leipzig, Department for Internal Medicine, Endocrinology and Nephrology, Leipzig, Germany
› Author Affiliations
Further Information

Publication History

received 22 February 2011

accepted 08 June 2011

Publication Date:
19 July 2011 (online)

Also available at
    Permissions and Reprints

Corrected by:

High Prevalence of TSHR/Gsα Mutation-negative Clonal Hot Thyroid Nodules (HNs) in a Turkish CohortHorm Metab Res 2011; 43(10): e1-e1
DOI: 10.1055/s-0031-1286299

Abstract

Whereas the majority of hot thyroid nodules are caused by somatic TSH-receptor mutations, the percentage of TSH-receptor mutation negative clonal hot nodules (HN) and thus the percentage of hot nodules likely caused by other somatic mutations are still debated. This is especially the case for toxic multinodular goiter (TMNG). 35 HNs [12 solitary hot nodules (SHN), 23 TMNG] were screened for somatic TSHR mutations in the exons 9 and 10 and for Gsα mutations in the exons 7 and 8 using DGGE. Determination of X-chromosome inactivation was used for clonality analysis. Overall TSHR mutations were detected in 14 out of 35 (40%) HNs. A nonrandom X-chromosome inactivation pattern was detected in 18 out of 25 (72%) HNs suggesting a clonal origin. Of 15 TSHR or Gsα mutation negative cases 13 (86.6%) showed nonrandom X-chromosome inactivation, indicating clonal origin. The frequency of activating TSHR and/or Gsα mutations was higher in SHNs (9 of 12) than in TMNGs (6 of 23). There was no significant difference for the incidence of clonality for HNs between TMNGs or SHNs (p: 0.6396). Activating TSHR and/or Gsα mutations were more frequent in SHNs than in TMNG. However, the frequency of clonality is similar for SHN and TMNG and there is no significant difference for the presence or absence of TSHR and/or Gsα mutations of clonal or polyclonal HNs. The high percentage of clonal mutation-negative HNs in SHN and TMNG suggests alternative molecular aberrations leading to the development of TSHR mutation negative nodules.

Key words

TSH-receptor mutation - clonality - toxic multinodular guatr - thyroid - solitary hot nodules
 

  • References

  • 1 Bishop JM. The molecular genetics of cancer. Science 1987; 235 (4786) 305-311
    CrossrefPubMedGoogle Scholar
  • 2 Wainscoat JS, Fey MF. Assessment of clonality in human tumors: a review. Cancer Res 1990; 50: 1355-1360
    PubMedGoogle Scholar
  • 3 Knudson Jr AG. Mutation and cancer: a personal odyssey. Adv Cancer Res 1995; 67: 1-23
    PubMedGoogle Scholar
  • 4 Dumont JE, Lamy F, Roger P, Maenhaut C. Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol Rev 1992; 72: 667-697
    CrossrefPubMedGoogle Scholar
  • 5 Bodenner DL, Lash RW. Thyroid disease mediated by molecular defects in cell surface and nuclear receptors. Am J Med 1998; 105: 524-538
    CrossrefPubMedGoogle Scholar
  • 6 Lyons J, Landis CA, Harsh G, Vallar L, Grünewald K, Feichtinger H, Duh QY, Clark OH, Kawasaki E, Bourne HR. Two G protein oncogenes in human endocrine tumors. Science 1990; 10 249 (4969) 655-659
    Google Scholar
  • 7 Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, Dumont J, Vassart G. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993; 365 (6447) 649-651
    Google Scholar
  • 8 Lyon MF. X-chromosome inactivation and developmental patterns in mammals. Biol Rev Camb Philos Soc 1972; 47: 1-35
    PubMedGoogle Scholar
  • 9 Fey MF, Peter HJ, Hinds HL, Zimmermann A, Liechti-Gallati S, Gerber H, Studer H, Tobler A. Clonal analysis of human tumors with M27 beta, a highly informative polymorphic X chromosomal probe. J Clin Invest 1992; 89: 1438-1444
    CrossrefPubMedGoogle Scholar
  • 10 Trülzsch B, Krohn K, Wonerow P, Chey S, Holzapfel HP, Ackermann F, Führer D, Paschke R. Detection of thyroid-stimulating hormone receptor and Gsalpha mutations: in 75 toxic thyroid nodules by denaturing gradient gel electrophoresis. J Mol Med 2001; 78: 684-691
    CrossrefPubMedGoogle Scholar
  • 11 Krohn K, Führer D, Holzapfel HP, Paschke R. Clonal origin of toxic thyroid nodules with constitutively activating thyrotropin receptor mutations. J Clin Endocrinol Metab 1998; 83: 130-134
    CrossrefPubMedGoogle Scholar
  • 12 Holzapfel HP, Führer D, Wonerow P, Weinland G, Scherbaum WA, Paschke R. Identification of constitutively activating somatic thyrotropin receptor mutations in a subset of toxic multinodular goiters. J Clin Endocrinol Metab 1997; 82: 4229-4233
    CrossrefPubMedGoogle Scholar
  • 13 Tumours of the Thyroid and Parathyroid: Follicular adenoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C. eds WHO Classification of Tumours: Pathology & Genetics of Tumours of Endocrine Organs. Lyon: IARC Press; 2004: 98-103
    Google Scholar
  • 14 Krohn K, Wohlgemuth S, Gerber H, Paschke R. Hot microscopic areas of iodine-deficient euthyroid goitres contain constitutively activating TSH receptor mutations. J Pathol 2000; 192: 37-42
    CrossrefPubMedGoogle Scholar
  • 15 Kozasa T, Itoh H, Tsukamoto T, Kaziro Y. Isolation and characterization of the human Gs alpha gene. Proc Natl Acad Sci USA 1988; 85: 2081-2085
    CrossrefPubMedGoogle Scholar
  • 16 Jäschke H, Neumann S, Moore S, Thomas CJ, Colson AO, Costanzi S, Kleinau G, Jiang JK, Paschke R, Raaka BM, Krause G, Gershengorn MC. A low molecular weight agonist signals by binding to the transmembrane domain of thyroid-stimulating hormone receptor (TSHR) and luteinizing hormone/chorionic gonadotropin receptor (LHCGR). Biol Chem 2006; 14 281: 9841-9844
    CrossrefPubMedGoogle Scholar
  • 17 Mueller S, Gozu HI, Bircan R, Jaeschke H, Eszlinger M, Lueblinghoff J, Krohn K, Paschke R. Background: Cases of Borderline In Vitro Constitutive Thyrotropin Receptor Activity: How to Decide Whether a Thyrotropin Receptor Mutation Is Constitutively Active or Not?. Thyroid 2009; 19: 765-773
    CrossrefPubMedGoogle Scholar
  • 18 Ballesteros JA, Jensen AD, Liapakis G, Søren, Rasmussen GF, Shi L, Gether U, Javitch JA. Activation of the b2-Adrenergic Receptor Involves Disruption of an Ionic Lock between the Cytoplasmic Ends of Transmembrane Segments 3 and 6. J Biol Chem 2001; 276: 29171-29177
    CrossrefPubMedGoogle Scholar
  • 19 Gozu HI, Bircan R, Krohn K, Muller S, Vural S, Gezen C, Sargin H, Yavuzer D, Sargin M, Cirakoglu B, Paschke R. Similar prevalence of somatic TSH receptor and Gsalpha mutations in toxic thyroid nodules in geographical regions with different iodine supply in Turkey. Eur J Endocrinol 2006; 155: 535-545
    CrossrefPubMedGoogle Scholar
  • 20 Russo D, Arturi F, Wicker R, Chazenbalk GD, Schlumberger M, DuVillard JA, Caillou B, Monier R, Rapoport B, Filetti S. Genetic alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab 1995; 80: 1347-1351
    CrossrefPubMedGoogle Scholar
  • 21 Nogueira CR, Kopp P, Arseven OK, Santos CL, Jameson JL, Medeiros-Neto G. Thyrotropin receptor mutations in hyperfunctioning thyroid adenomas from Brazil. Thyroid 1999; 9: 1063-1068
    CrossrefPubMedGoogle Scholar
  • 22 Tonacchera M, Agretti P, Chiovato L, Rosellini V, Ceccarini G, Perri A, Viacava P, Naccarato AG, Miccoli P, Pinchera A, Vitti P. Activating thyrotropin receptor mutations are present in nonadenomatous hyperfunctioning nodules of toxic or autonomous multinodular goiter. J Clin Endocrinol Metab 2000; 85: 2270-2274
    CrossrefPubMedGoogle Scholar
  • 23 Vanvooren V, Uchino S, Duprez L, Costa MJ, Vandekerckhove J, Parma J, Vassart G, Dumont JE, Van Sande J, Noguchi S. Oncogenic mutations in the thyrotropin receptor of autonomously functioning thyroid nodules in the Japanese population. Eur J Endocrinol 2002; 147: 287-291
    CrossrefPubMedGoogle Scholar
  • 24 Georgopoulos NA, Sykiotis GP, Sgourou A, Papachatzopoulou A, Markou KB, Kyriazopoulou V, Papavassiliou AG, Vagenakis AG. Autonomously functioning thyroid nodules in a former iodine-deficient area commonly harbor gain-of-function mutations in the thyrotropin signaling pathway. Eur J Endocrinol 2003; 149: 287-292
    CrossrefPubMedGoogle Scholar
  • 25 Tassi V, Di Cerbo A, Porcellini A, Papini E, Cisternino C, Crescenzi A, Scillitani A, Pizzuti A, Ratti A, Trischitta V, Avvedimento VE, Fenzi G, De Filippis V. Screening of thyrotropin receptor mutations by fine-needle aspiration biopsy in autonomous functioning thyroid nodules in multinodular goiters. Thyroid 1999; 9: 353-357
    CrossrefPubMedGoogle Scholar
  • 26 Tonacchera M, Chiovato L, Pinchera A, Agretti P, Fiore E, Cetani F, Rocchi R, Viacava P, Miccoli P, Vitti P. Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma. J Clin Endocrinol Metab 1998; 83: 492-498
    CrossrefPubMedGoogle Scholar
  • 27 Führer D, Holzapfel HP, Wonerow P, Scherbaum WA, Paschke R. Somatic mutations in the thyrotropin receptor gene and not in the Gs alpha protein gene in 31 toxic thyroid nodules. J Clin Endocrinol Metab 1997; 82: 3885-3891
    CrossrefPubMedGoogle Scholar
  • 28 O’Sullivan C, Barton CM, Staddon SL, Brown CL, Lemoine NR. Activating point mutations of the gsp oncogene in human thyroid adenomas. Mol Carcinog 1991; 4: 345-349
    CrossrefPubMedGoogle Scholar
  • 29 Parma J, Duprez L, Van Sande J, Hermans J, Rocmans P, Van Vliet G, Costagliola S, Rodien P, Dumont JE, Vassart G. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. J Clin Endocrinol Metab 1997; 82: 2695-2701
    CrossrefPubMedGoogle Scholar
  • 30 Paschke R, Tonacchera M, Van Sande J, Parma J, Vassart G. Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid. J Clin Endocrinol Metab 1994; 79: 1785-1789
    CrossrefPubMedGoogle Scholar
  • 31 Russo D, Arturi F, Suarez HG, Schlumberger M, Du Villard JA, Crocetti U, Filetti S. Thyrotropin receptor gene alterations in thyroid hyperfunctioning. J Clin Endocrinol Metab 1996; 81: 1548-1551
    CrossrefPubMedGoogle Scholar
  • 32 Palos-Paz F, Perez-Guerra O, Cameselle-Teijeiro J, Rueda-Chimeno C, Barreiro-Morandeira F, Lado-Abeal J, Galician Group for the Study of Toxic Multinodular Goitre. Araujo Vilar D, Argueso R, Barca O, Botana M, Cabezas-Agrícola JM, Catalina P, Dominguez Gerpe L, Fernandez T, Mato A, Nuño A, Penin M, Victoria B. Prevalence of mutations in TSHR, GNAS, PRKAR1A and RAS genes in a large series of toxic thyroid adenomas from Galicia, an iodine-deficient area in NW Spain. Eur J Endocrinol 2008; 159: 623-631
    CrossrefPubMedGoogle Scholar
  • 33 Porcellini A, Ciullo I, Laviola L, Amabile G, Fenzi G, Avvedimento VE. Novel mutations of thyrotropin receptor gene in thyroid hyperfunctioning adenomas. Rapid identification by fine needle aspiration biopsy. J Clin Endocrinol Metab 1994; 79: 657-661
    CrossrefPubMedGoogle Scholar
  • 34 Takeshita A, Nagayama Y, Yokoyama N, Ishikawa N, Ito K, Yamashita T, Obara T, Murakami Y, Kuma K, Takamatsu J. Rarity of oncogenic mutations in the thyrotropin receptor of autonomously functioning thyroid nodules in Japan. J Clin Endocrinol Metab 1995; 80: 2607-2611
    CrossrefPubMedGoogle Scholar
  • 35 Führer D, Kubisch C, Scheibler U, Lamesch P, Krohn K, Paschke R. The extracellular thyrotropin receptor domain is not a major candidate for mutations in toxic thyroid nodules. Thyroid 1998; 8: 997-1001
    CrossrefPubMedGoogle Scholar
  • 36 Salmon I, Kiss R, Franc B, Gasperin P, Heimann R, Pasteels JL, Verhest A. Comparison of morphonuclear features in normal, benign and neoplastic thyroid tissue by digital cell image analysis. Anal Quant Cytol Histol 1992; 14: 47-54
    PubMedGoogle Scholar
  • 37 Salmon I, Gasperin P, Pasteels JL, Heimann R, Kiss R. Relationship between histopathologic typing and morphonuclear assessments of 238 thyroid lesions. Digital cell image analysis performed on Feulgen-stained nuclei from formalin-fixed, paraffin-embedded materials. Am J Clin Pathol 1992; 97: 776-786
    PubMedGoogle Scholar
  • 38 Hegedüs L, Paschke R, Krohn K, Bonnema SJ. In: Endocrinology. 6th edition James JL, DeGroot eds Philadelphia: Saunders Elsevier; 2010: 1636-1649
    Google Scholar
  • 39 Cetani F, Tonacchera M, Vassart G. Differential effects of NaCl concentration on the constitutive activity of the thyrotropin and the luteinizing hormone/chorionic gonadotropin receptors. FEBS Lett 1996; 378: 27-31
    CrossrefPubMedGoogle Scholar